ASH Clinical News ACN_4.1_FULL_ISSUE_DIGITAL | Page 22

INTRODUCING A NEW
CAR T THERAPY
Find a list of authorized treatment centers
at YESCARTA.com/centers
INDICATION
YESCARTA™ is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult
patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large
B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma,
and DLBCL arising from follicular lymphoma.
Limitation of Use: YESCARTA™ is not indicated for the treatment of patients with primary central nervous system lymphoma.
IMPORTANT SAFETY INFORMATION
WARNING: CYTOKINE RELEASE SYNDROME AND NEUROLOGIC TOXICITIES
• Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving
YESCARTA™. Do not administer YESCARTA™ to patients with active infection or inflammatory disorders. Treat
severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids [see Dosage and Administration
(2.2, 2.3), Warnings and Precautions (5.1)].
• Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving YESCARTA™,
including concurrently with CRS or after CRS resolution. Monitor for neurologic toxicities after treatment with
YESCARTA™. Provide supportive care and/or corticosteroids as needed [see Dosage and Administration (2.2, 2.3),
Warnings and Precautions (5.2)].
• YESCARTA™ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS)
called the YESCARTA™ REMS [see Warnings and Precautions (5.3)].
Important Safety Information continued on adjacent page.
YESCARTA is a trademark of Kite Pharma.
© 2017 Kite Pharma | PRC-00145 10/2017
008955_Kite_Yescarta_PI-based_Ad_ASHClnclNews_120117_RL.indd 1-2